NASDAQ:JBIO | Free Cash Flow | Jade Biosciences, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$24.08M
2025-12-31-$33.65M$3,000.00-$33.65M
2025-03-31-$18.76M
2024-12-31-$11.05M
2024-09-30-$6.8M
2024-03-31-$23.67M
2023-12-31-$14.8M$64,000.00-$14.86M
2023-03-31-$11.42M$16,000.00-$11.44M
2022-12-31-$14.87M$4,000.00-$14.87M
2022-03-31-$5.66M$28,000.00-$5.69M
2021-12-31-$13.09M$85,000.00-$13.18M
2021-03-31-$3.78M$40,000.00-$3.82M
2020-12-31-$2.88M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$94.69M$196,000.00-$94.89M
2024-12-31-$71.2M
2023-12-31-$56.78M$142,000.00-$56.92M
2022-12-31-$39.12M$195,000.00-$39.32M
2021-12-31-$27.4M$181,000.00-$27.58M
2020-12-31-$7.86M